VANFLYTA Film-coated tablet Ref.[51535] Active ingredients: Quizartinib

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, 81379 Munich, Germany

Product name and form

VANFLYTA 17.7 mg film-coated tablets.

VANFLYTA 26.5 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet (tablet).

VANFLYTA 17.7 mg film-coated tablets: White, round-shaped film-coated tablets, 8.9 mm in diameter and debossed with ‘DSC 511’ on one side.

VANFLYTA 26.5 mg film-coated tablets: Yellow, round-shaped film-coated tablets, 10.2 mm in diameter and debossed with ‘DSC 512’ on one side.

Qualitative and quantitative composition

VANFLYTA 17.7 mg film-coated tablets: Each film-coated tablet contains 17.7 mg quizartinib (as dihydrochloride).

VANFLYTA 26.5 mg film-coated tablets: Each film-coated tablet contains 26.5 mg quizartinib (as dihydrochloride).

For the full list of excipients, see section 6.1.

Active Ingredient Description
Quizartinib

Quizartinib is an inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major metabolite AC886 competitively bind to the adenosine triphosphate (ATP) binding pocket of FLT3 with high affinity. Quizartinib and AC886 inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting further downstream FLT3 receptor signalling and blocking FLT3-ITDdependent cell proliferation.

List of Excipients

VANFLYTA 17.7 mg film-coated tablets

Tablet core:

Hydroxypropylbetadex
Cellulose, microcrystalline (E460)
Magnesium stearate

Film-coating:

Hypromellose (E464)
Talc (E553b)
Triacetin (E1518)
Titanium dioxide (E171)

VANFLYTA 26.5 mg film-coated tablets

Tablet core:

Hydroxypropylbetadex
Cellulose, microcrystalline (E460)
Magnesium stearate

Film-coating:

Hypromellose (E464)
Talc (E553b)
Triacetin (E1518)
Titanium dioxide (E171)
Yellow iron oxide (E172)

Pack sizes and marketing

Aluminium/aluminium perforated unit dose blisters.

VANFLYTA 17.7 mg film-coated tablets: Cartons containing 14 × 1 or 28 × 1 film-coated tablets.

VANFLYTA 26.5 mg film-coated tablets: Cartons containing 14 × 1, 28 × 1 or 56 × 1 film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, 81379 Munich, Germany

Marketing authorization dates and numbers

EU/1/23/1768/001-005

Drugs

Drug Countries
VANFLYTA Austria, Estonia, France, Croatia, Ireland, Italy, Japan, Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.